Invivyd, Inc. (NASDAQ: IVVD)

Invivyd, Inc. is a biopharmaceutical company focused on the discovery development and commercialization of monoclonal antibody therapies for the prevention and treatment of serious viral infectious diseases. The company’s initial target is COVID 19 with plans to expand into respiratory syncytial virus and measles. Its lead product PEMGARDA received emergency use authorization from the U S Food and Drug Administration in March 2024 for pre exposure prophylaxis of COVID 19 in immunocompromised adults and adolescents. Invivyd is advancing a next generation monoclonal antibody candidate VYD2311 for COVID 19 and has preclinical programs for respiratory syncytial virus and measles. The company leverages a proprietary antibody discovery platform and a partnership with Adimab to engineer half life extended molecules designed to retain activity against evolving virus variants. Invivyd’s strategy centers on delivering protection to vulnerable populations by creating antibodies that can be updated quickly as new variants emerge. The firm also invests in variant monitoring and structural analysis to inform its engineering efforts. Through internal research and external collaborations it seeks to build a broad pipeline of product candidates that address multiple high need viral threats.

Invivyd generates revenue principally from the sale of PEMGARDA to specialty distributors and directly to infusion centers healthcare providers and provider institutions in the United States. During the year ended December 31 2025 the company recorded net product revenue from sales to three specialty distributors that accounted for 46 percent 23 percent and 17 percent of total gross sales. In addition to product sales the company receives milestone payments from its collaboration agreements with Adimab and may earn royalties on net sales of licensed products. Future revenue streams may include sales of VYD2311 upon regulatory approval milestone payments from collaborations and royalties on licensed technologies. The company does not currently operate manufacturing facilities and relies on contract manufacturing organizations for drug substance and drug product supply. Invivyd has entered into long term master services agreements with WuXi Biologics to secure manufacturing capacity for PEMGARDA and VYD2311. These agreements provide for the purchase of drug substance and drug product for both clinical and commercial supply. The firm also works with third party logistics providers to distribute its product to end users of care.

Invivyd competes in the monoclonal antibody and antiviral markets alongside large pharmaceutical companies such as AstraZeneca Roche Merck Pfizer Gilead and biotechnology firms developing COVID 19 therapies. It also faces competition from vaccine manufacturers Moderna Pfizer BioNTech Novavax and from other prophylactic antibodies targeting respiratory syncytial virus and measles. The company’s competitive advantages stem from its proprietary antibody discovery platform its exclusive access to Adimab’s B cell mining and antibody engineering capabilities and its focus on half life extended molecules that aim to reduce viral escape. Invivyd benefits from Fast Track designation for VYD2311 and from a proactive variant monitoring program that informs its engineering efforts. The firm’s partnership with Adimab provides access to industry leading antibody mining optimization and developability screening tools. Invivyd’s approach emphasizes the identification of broadly neutralizing antibodies that target conserved epitopes on the spike protein reducing the risk of viral escape. The company also leverages its experience with adintrevimab and PEMGARDA to accelerate preclinical and clinical development of new candidates. These factors position the company to address unmet needs in immunocompromised populations and to respond quickly to emerging virus strains.

The company serves immunocompromised patients who receive care from hematology oncology rheumatology and transplant specialists. Its customers include healthcare providers infusion centers hospitals and provider institutions that administer PEMGARDA under medical supervision. Distribution is handled through three major specialty distributors that sell the product to end user sites of care. While the filing does not disclose the specific names of these distributors it notes that they collectively represent the majority of gross sales. Invivyd’s customer base is concentrated in the United States where the emergency use authorization for PEMGARDA applies. The firm also engages with academic medical centers and specialty clinics that treat patients with underlying immune deficiencies. These relationships help inform real world usage and support ongoing safety and effectiveness monitoring of its products. In addition Invivyd collaborates with patient advocacy groups to raise awareness about preventive options for immunocompromised individuals. The company collects feedback from treating physicians to refine its medical affairs and outreach efforts.